Medical Condition News

RSS

Early diagnosis of AD may prevent psychological and behavioral symptoms

Persons with Alzheimer's disease are able to manage their everyday activities longer and they suffer from less psychological and behavioural symptoms if the diagnosis is made and treatment begun at a very early phase of the disease, indicates a recent study conducted at the University of Eastern Finland.

19 Jul 2013

Study shows link between reclassification of cannabis, hospital admissions for cannabis psychosis

Researchers from the University of York have demonstrated that the change in cannabis declassification in 2009 has coincided with a significant increase in hospital admissions for cannabis psychosis - rather than the decrease it was intended to produce.

19 Jul 2013

Depressive disorder patients exhibit negative bias brain imaging changes and cognitive dysfunction

...

19 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.

19 Jul 2013

Idera Pharmaceuticals receives patent related to IMO-8400

Idera Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400.

19 Jul 2013

Researchers identify genetic cause of severe obesity

Researchers at Boston Children's Hospital have identified a genetic cause of severe obesity that, though rare, raises new questions about weight gain and energy use in the general obese population. The research, published in the journal Science on July 19, involved genetic surveys of several groups of obese humans and experiments in mice.

19 Jul 2013

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

ARMAGEN announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II).

19 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Ecological framework provides better understanding of health-related quality of life in Parkinson's patients

Bronfenbrenner's ecological systems theory emphasizes the development of a series of nested environment systems with which an individual interacts. These systems interact with the individual, and also affect the development of the individual.

19 Jul 2013

NGM Biopharmaceuticals announces completion of $50 million Series C financing

NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases.

19 Jul 2013

Researchers develop new drug delivery technique for diabetes treatment

Researchers have developed a drug delivery technique for diabetes treatment in which a sponge-like material surrounds an insulin core. The sponge expands and contracts in response to blood sugar levels to release insulin as needed. The technique could also be used for targeted drug delivery to cancer cells.

19 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

CHOP-led research increases numbers of patients who could be treated with gene therapy

Gene therapy researchers have produced a bioengineered decoy that fools the immune system and prevents it from mistakenly defeating the benefits delivered by a corrective gene.

18 Jul 2013

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Transition Therapeutics Inc. announced that the US Food and Drug Administration has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms in Alzheimer's disease.

18 Jul 2013

Medical Condition News

Early diagnosis of AD may prevent psychological and behavioral symptoms

Study shows link between reclassification of cannabis, hospital admissions for cannabis psychosis

Depressive disorder patients exhibit negative bias brain imaging changes and cognitive dysfunction

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Idera Pharmaceuticals receives patent related to IMO-8400

Researchers identify genetic cause of severe obesity

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Ecological framework provides better understanding of health-related quality of life in Parkinson's patients

NGM Biopharmaceuticals announces completion of $50 million Series C financing

Researchers develop new drug delivery technique for diabetes treatment

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

CHOP-led research increases numbers of patients who could be treated with gene therapy

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News